A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY IN HEALTHY ADULT PARTICIPANTS TO ASSESS THE MASS BALANCE,ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND PHARMACOKINETICS OF [14C]PF-07248144 USING A 14C-MICROTRACER APPROACH
Latest Information Update: 02 Mar 2026
At a glance
- Drugs Prifetrastat (Primary) ; Prifetrastat (Primary)
- Indications Breast cancer; HER2 negative breast cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 02 Mar 2026 New trial record